NVP-BKM120

01/01/2017 - "On the basis of the finding that PI3K inhibition resulted in a more inflammatory tumor leukocyte infiltrate, the therapeutic efficacy of BKM120 (30 mg/kg, every day) and anti-PD1 (100 μg, twice weekly) was evaluated in PyMT tumor-bearing mice.Results"
01/24/2017 - "Autophagy inhibition augmented the efficacy of BKM120 depending on PIK3CA-mutant cancer cell type. "
11/29/2021 - "Our study revealed that HCQ and BKM120 synergistically increased DSBs in tumor cells and therefore augmented apoptosis, resulting in enhanced antitumor efficacy. "
11/05/2019 - "Future studies may provide insight into buparlisib efficacy by refining the molecular selection of different tumor types."
11/05/2019 - "Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study."

11/01/2019 - "Neoadjuvant buparlisib may provide some efficacy for breast cancer, but leads to the increase in serious adverse events."
11/01/2019 - "The efficacy of neoadjuvant buparlisib for breast cancer remains controversial. "
12/01/2017 - "Efficacy of buparlisib in treating breast cancer."
11/01/2019 - "We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through May 2019 for randomized controlled trials (RCTs) assessing the efficacy and safety of neoadjuvant buparlisib versus placebo for breast cancer. "
11/01/2019 - "The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies."

02/01/2021 - "With a maximum tolerated dose of 100 mg/day and an acceptable toxicity profile, buparlisib may be effective in HNSCC, irrespective of PIK3CA mutational status. "
02/01/2021 - "A summary of the safety and efficacy of buparlisib, a class I pan-PI3K inhibitor, from several phase I and phase II HNSCC trials is provided. "
11/01/2020 - "In this study we demonstrate the effects of PI3K/Akt/mTOR pathway inhibition by buparlisib on PD-L1 expression in HNSCC cell lines. "
02/01/2021 - "An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma."
11/01/2020 - "After buparlisib treatment for 72 h, PD-L1 was downregulated in total cell lysates of HNSCC cells. "

01/01/2019 - "Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma."
01/01/2019 - "We assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radiotherapy in patients with non-small cell lung carcinoma (NSCLC) and investigated its effect on tumour hypoxia. "
10/11/2016 - "Thus, the current study not only reveals mechanisms accounting for BKM120-induced autophagy, but also suggests an alternative method to enhance BKM120's therapeutic efficacy against non-small cell lung cancer(NSCLC) by blocking autophagy with either a lysosomal protease inhibitor or MEK inhibitor."
09/01/2015 - "Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study."

04/01/2012 - "In this study, we examined the efficacy of NVP-BKM120, a pan-class I PI3K inhibitor in human gastric cancer cells and hypothesized that the combined inhibition of PI3K and STAT3 would be synergistic in KRAS mutant gastric cancer cells. "
04/01/2012 - " In KRAS mutant gastric cancer cells, either p-ERK or p-STAT3 was also increased upon treatment of NVP-BKM120. "
04/01/2012 - "NVP-BKM120 demonstrated anti-proliferative activity in 11 human gastric cancer cell lines by decreasing mTOR downstream signaling. "
04/01/2012 - "NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations."
06/01/2012 - "Human gastric cancer cells were less sensitive to both BEZ235 and BKM120. "